Redox State in the Course of Chronic Renal Insufficiency and Hemodialysis: Implications in Morbimortality

Overview

The influence of hemodialysis on oxidative stress, endothelial activation, inflammation and on the redox state of lymphocytes should be clarified as well as the putative relationships between all these parameters.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 2012

Detailed Description

Up to now, no anti-oxydative treatment has been able to reduce the mortality of the patients with Kidney Failure. Thus it is necessary to have a better knowledge of oxydative stress mechanisms in patients with KF in order to find more efficacious treatments. The influence of hemodialysis upon oxidative stress is not well known.

Interventions

  • Other: Sampling of blood
    • A sampling of blood will be made
  • Other: Sampling of blood
    • A sampling of bood will be made before the dialysis
  • Other: Sampling of blood
    • A sampling of blood will be made.

Arms, Groups and Cohorts

  • Other: 1
    • Volunteer healthy
  • Other: 2
    • Patient dialysis patient
  • Other: 3
    • Not dialysed chronic renal insufficient patient

Clinical Trial Outcome Measures

Primary Measures

  • This study should allow to clarify the redox state some plasma by quantification of thiols membranous on the surface of lymphocytes at the hemodialysis and insufficient renal chronic not dialysed patients.
    • Time Frame: 48 months

Secondary Measures

  • This study should allow to estimate in a forward-looking longitudinal plan the possible involvement of the parameters of the redox state and the morbidity and the cardiovascular and global mortality in 2 years in 2 studied populations.
    • Time Frame: 48 months

Participating in This Clinical Trial

Inclusion Criteria

  • 18 and 80 years old man or woman dialysing at least 3 times a week for at least 6 months and having no residual renal function
  • Rate of haemoglobin > 11 g / dl
  • Clinically stable patient that is having had no considerable event (cardiovascular problem, infection, surgical operation) with the exception of angioplasty of fistula or prosthesis vascular, in the previous 3 months the entrance to the study
  • Patient capable of understanding and of following the essay, in particular knowing how to read the note of information.

Exclusion Criteria

  • Pregnant woman
  • Treatment by corticoids or immunosuppresseurs
  • hemopathy sly
  • chronic cancer or infection in evolution
  • Cardiovascular event (infarct, unstable angor, coronary bypasses, confusions of the rhythm, AVC, amputation) or infectious (blood-poisoning, pneumopathie, meningitis) or surgical operation in the previous 3 months the inclusion in the study.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Assistance Publique Hopitaux De Marseille
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Bertrand DUSSOL, MD, Principal Investigator, Assistance Publique des Hopitaux de Marseille

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.